There is a five-to-seven-day course of pills you start two days before your period β a long-half-life triptan, or naproxen at the dose you would use for serious cramps β that has cleared randomised trials for stopping the attack outright. If you do not get visual auras before your headaches, switching combined hormonal contraception to continuous dosing (no hormone-free week) removes the trigger in most women. If you do get auras, the combined pill itself comes off the table: in women with aura it multiplies stroke risk roughly six-fold. Two cycles of tracking tell you which arm applies.
The cycle is running a chemistry problem with a clean shape. Your ovaries hold estrogen high through the second half of the cycle and let it fall sharply in the 48 hours before bleeding starts. The trigeminal nerve β the big sensory nerve in your face and forehead, the one that fires in every kind of migraine β has receptors that read that fall as a release signal. It unloads a peptide called CGRP, the brain's blood vessels light up and sensitise, and the attack starts Raffaelli 2023.
The cramps you get on day one of your period run on a related but separate pathway β prostaglandins released by the shedding lining of the womb β which is why a strong anti-inflammatory dose can dent both the cramps and the headache Sances 2008. It is not the same machinery, though, and an anti-inflammatory taken on day one of bleeding does not catch the trigger that fired two days earlier. The estrogen drop is the event; the cramping is a parallel story.
How well it is actually treatable
The short-term prevention protocol β a course of pills timed to your cycle β has the kind of trial backing you would want before reorganising a year of your life around it. Two long-half-life triptans cleared placebo-controlled trials at the same window: start two days before your expected period, continue through day three of bleeding. Both roughly doubled the share of monthly perimenstrual stretches that ended headache-free Silberstein 2004 Newman 2001. A high-dose anti-inflammatory across the same window did similar work at smaller scale and lower cost Sances 2008.
The diagnostic criteria themselves are validated against prospective cycle diaries, the only honest standard for a condition defined by timing Verhagen 2022. The current international classification puts the threshold at attacks on day -2 through day +3 of menstruation, in at least two of three cycles tracked ICHD-3 2018. If your pattern matches that, the trials apply to you.
What untreated menstrual migraine has been costing you
The cost is invisible because it has been there since you were a teenager. Twelve cycles a year, one to three high-disability days each, plus the slow postdrome and the anticipatory hum of "it is coming on day one" β call it on the order of thirty days a year that have not really been yours. The nights inside the attack window are broken too: pain wakes you, the next day starts behind, the week becomes its own small jet-lag. The compounding shape is what people miss. The Friday plan you turned down five years running because of where it fell in your cycle. The deadline you have been quietly moving so it never lands in the wrong week. The trip you booked around it. The version of you your partner has met one week a month for a decade.
In the AMPP population study, women with menstrually associated migraine carried higher disability scores, more anxiety and depression, and more lost workdays than women whose migraines did not track menses, even after matching on attack frequency PavloviΔ 2015. Perimenstrual attacks last 37 to 50 percent longer than the same woman's attacks at other times of her cycle, hurt more, and come back within twenty-four hours of treatment more often MacGregor 2021. The week you have been writing off as PMS has been writing on you for fifteen years.
The plan, in order
Three layers, sequenced. Track first, because the timed prevention only works if you know when day minus two actually is. Then run the prevention course in the next confirmed cycle. Then, if you are on or considering combined hormonal contraception and you do not get visual aura before headaches, the structural switch that often makes the whole protocol unnecessary.
If your cycles are irregular β and the prevention window keeps missing because you cannot predict day minus two β the structural switch (continuous combined hormonal contraception, if you do not have aura) is the cleaner play than chasing the window. If you have aura, skip to the next section before any contraceptive call.
If you get visual aura, read this before any contraceptive prescription
One safety call dominates the rest of the entry. If you get a visual warning before your headache β a shimmer, a zigzag that grows across half your field of vision over fifteen to thirty minutes, a blind spot, sparkles β you have migraine with aura. The combined hormonal pill (or patch, or ring) is contraindicated in this group, and not for a soft reason. The combination of estrogen-containing contraception and migraine with aura raises ischemic stroke risk roughly six-fold over either factor on its own β a finding consistent across the systematic-review literature Sheikh 2018. The World Health Organization's eligibility criteria put it in the strictest "do not use" category for women with aura over 35, and in the avoid-where-possible category under 35 WHO MEC 2015.
Two further checks before the triptan part of the protocol. Triptans should not be used if you have uncontrolled high blood pressure, known coronary disease, a prior stroke or transient ischemic attack, or are pregnant. The high-dose anti-inflammatory option is off the table if you have a peptic ulcer history, kidney disease, are on blood thinners, or are in the third trimester of pregnancy. The progestin-only pill, the levonorgestrel IUD, and the implant carry none of the aura-related stroke concerns and remain available across both groups.
Three things almost everyone gets wrong
"My period headaches are normal." A headache severe enough to put you in a dark room, recurring on the same day of two or three consecutive cycles, is not a worse period. It is a diagnosable condition with cycle-targeted treatments that the protocol for your other headaches does not catch. Period pain and menstrual migraine often arrive on the same day in the same body; the cramps run on prostaglandins, the migraine runs on the estrogen-CGRP pathway, and treating one does not treat the other.
"The pill helps menstrual migraine." The standard combined hormonal pill with the seven-day pill-free week makes it worse for most women. That week off is, biochemically, a manufactured estrogen drop β and you have just added a second one to the month, sharper than the natural one. Continuous dosing (skipping the placebo week) is the configuration that helps; cyclic dosing is the one that hurts. And for women with aura, no combined pill regimen of any kind is the right answer β see the previous section.
"It is just my usual migraine, on a worse day." Within-woman analyses say otherwise. The same woman's perimenstrual attacks last 37 to 50 percent longer than her non-perimenstrual ones, hit harder, respond worse to a single dose of acute treatment, and come back within twenty-four hours of treatment more often MacGregor 2021. The Wednesday-attack triptan strategy underperforms on a day-one attack. Different timing, different course, different drugs β and that is why the protocol exists.
The protocol changes at the edges
Through perimenopause
Through the years before menopause, attacks usually get worse before they get better. The estrogen drops grow larger, arrive on no predictable schedule, and the cycle-tracking machinery the rest of the protocol depends on stops working. This is the stretch in which short-term prevention starts mistiming itself and many women decide it has "stopped working" β really the trigger has stopped being predictable. Two things help: low-dose continuous transdermal estradiol (a patch or gel, applied daily without breaks) smooths the underlying drop; oral cyclic hormone-replacement regimens often make it worse by adding more drops MacGregor 2021. The bad stretch typically resolves in the first year or two after periods stop.
In pregnancy
Pregnancy is the one stretch in which most women with menstrual migraine get a real break. Roughly 60 to 80 percent improve substantially by the second trimester and a higher share by the third, as estradiol rises thirty- to forty-fold over its cycle peak and stops fluctuating altogether. Attacks tend to come back postpartum on the estrogen crash; the protocol resumes then. Triptans are a discussed-with-clinician call in pregnancy; high-dose anti-inflammatories are off the table in the third trimester.
For women with aura, the contraceptive arm of the protocol is different (previous section), but the mini-prevention windows β the triptan and the anti-inflammatory courses β are the same. Aura status changes the contraceptive call; it does not change the preventive timing.
Where this goes wrong in practice
Mistiming the prevention window. Starting frovatriptan or naproxen on day one of bleeding is the most common version of "I tried it and it did not work." The trigger has already fired forty-eight hours earlier; you are treating downstream. The prevention course has to land in the 48 hours before the attack, which only works if you have tracked your cycle long enough to know when those hours actually are. Two cycles of confirmation before starting is the minimum.
Treating recurrence as failure. Perimenstrual attacks come back within twenty-four hours of acute treatment more often than non-perimenstrual ones do. A single triptan dose that wears off is not the verdict that "triptans do not work for me" β it is the cue to switch to a long-half-life agent like frovatriptan or naratriptan, or to schedule a second dose at the recurrence window. The standard-issue first-line triptan is tuned for a Wednesday attack, not a day-one menstrual one.
Missing aura entirely. Most women with mild visual aura have never been asked the right question β they have a shimmer or a blind spot for fifteen minutes before the headache and assume it is normal. It changes the contraceptive call completely. If anything in your visual field acts strangely in the lead-in to a headache, write it down and tell your clinician by name.
Going to combined hormonal contraception without screening for aura first. The pill is widely prescribed for "period problems" including menstrual migraine. Without an aura screen first, the prescription is a coin flip on stroke risk in the small subgroup it most affects. The fix is upstream of the prescription, not after it.
What changes if you run the protocol
By the first cycle of a correctly timed mini-prevention course, the wreckage that was nearly certain becomes a soft headache or nothing. The Silberstein trial numbers are roughly the felt experience: more headache-free perimenstrual stretches than not. By the third cycle, the anticipatory hum that has been a constant since you were a teenager β the half-awareness that you are heading into the bad week β starts to fade, because your body's prediction stops getting confirmed.
By the end of the first year, you have something on the order of twenty to thirty days back. Not as a metaphor. The AMPP disability gap between women with menstrually associated and non-associated migraine is the gap you have been carrying; closing it shows up as days you used to lose that you now keep PavloviΔ 2015. The Friday plan you used to forfeit. The deadline you used to slip. The trip you used to book around the wrong week. The version of you your partner has met one week a month for a decade starts showing up the other three weeks too.
On the longer arc β and this is the under-told part β the perimenopause stretch that worsens migraine for most women becomes a known, navigable thing instead of an ambush. You enter it with a playbook and the awareness that for most women it resolves on the other side. And if you have aura, the contraceptive call you make today is also the stroke at thirty-five that you are not going to have.
Adjacent topics worth knowing about, briefly: general migraine prevention (sleep regularity, daily preventives like propranolol and topiramate, the newer monthly CGRP-blocking injections for women whose attacks are not only menstrual); premenstrual dysphoric disorder, which overlaps in timing and mood-cost but runs on a different mechanism; endometriosis, which interacts with cycle pain in ways that complicate the diagnostic picture; the menopause transition itself, which is the next stop on the same hormonal arc.
Substance and claimed effects
Menstrual migraine refers to migraine attacks that cluster in a narrow perimenstrual window β days -2 to +3 of menstruation (the day before bleeding starts through the third day of flow), recurring in at least two of three cycles ICHD-3, 2018. The triggering event is a sharp drop in circulating estradiol in the late luteal phase, which the trigeminovascular system reads as a permissive signal for attack initiation Raffaelli et al. 2023. Two ICHD-3 appendix subtypes: pure menstrual migraine (PMM) β attacks only in the perimenstrual window β and menstrually related migraine (MRM) β perimenstrual attacks plus attacks at other cycle points. PMM is rare (under 1% of women with migraine in validation studies) Verhagen et al. 2022; MRM is the dominant clinical reality, accounting for the majority of "menstrual" attacks.
Claimed effects of recognising and treating menstrual migraine as a distinct entity, across catalogue dimensions: substantial short-term quality-of-life lift (1β3 days of disabling pain per cycle prevented or shortened); reduced fatigue / focus loss across the perimenstrual week; mood stabilisation by removing predictable monthly dread and a recurring painβsleepβdepression loop; a contraceptive-choice consequence (combined hormonal contraceptives + migraine with aura raise ischemic stroke risk roughly 6-fold over either alone Sheikh et al. 2018); a longevity-adjacent benefit via that same vascular-risk avoidance. Negligible direct or cumulative beauty effects.
Evidence by addressing question
mechanism
The estrogen-withdrawal hypothesis is the dominant model. Somerville's 1972 experiments remain the seminal demonstration: artificially maintaining late-luteal estradiol with intramuscular estradiol valerate delayed menstrual migraine onset, but did not delay menses itself β isolating the estrogen drop, not the bleed, as the trigger Raffaelli et al. 2023. The PavloviΔ SWAN cohort showed that women with migraine experience a steeper rate of estradiol decline in the two days preceding menses than women without migraine, despite similar peak levels PavloviΔ et al. 2016. Raffaelli's 2023 systematic re-review concludes the hypothesis is widely accepted but rests on a thin evidence base: small N, methodologic inconsistency, and no decisive controlled estradiol-clamp trial.
Downstream: estrogen modulates CGRP release in the trigeminovascular system. Estrogen receptors are densely expressed on CGRP-containing trigeminal neurons; in ovariectomised rats, falling estradiol increases trigeminal CGRP expression, reversed by estradiol replacement Labastida-Ramirez et al. 2019. The premenstrual estrogen drop is read by these neurons as a release signal β CGRP unloads, the trigeminovascular system sensitises, and the attack initiates. A parallel mechanism contributes: rising perimenstrual prostaglandin (especially PGE2) released from the shedding endometrium amplifies CGRP release and lowers nociceptive threshold, which is why NSAIDs β which block prostaglandin synthesis β work as both short-term preventives and acute treatment Sances et al. 2008.
evidence
Frovatriptan has the strongest short-term preventive evidence. Silberstein's 2004 randomised trial (N=546) of frovatriptan 2.5 mg twice daily started 2 days before expected menses and continued for 6 days reduced headache-free perimenstrual periods to a mean of 0.92 vs 0.42 on placebo (P<0.001) Silberstein et al. 2004. Naratriptan 1 mg twice daily for 5 days starting 2 days before menses: 50% of perimenstrual periods headache-free vs 25% placebo (P=0.003) Newman et al. 2001. The Hu meta-analysis pooling triptan short-term prevention (frovatriptan, naratriptan, zolmitriptan) concluded all three significantly reduce perimenstrual migraine incidence; frovatriptan has the lowest 24-hour recurrence rate due to its long half-life Hu et al. 2013.
NSAIDs. Naproxen sodium 550 mg twice daily started 1β2 days before expected menses and continued for 5β7 days has positive (smaller) RCT evidence for both prevention and reduction of severity, with the mechanism well-aligned to the prostaglandin component Sances et al. 2008. Mefenamic acid 500 mg three times daily has similar evidence.
Transdermal estradiol for perimenstrual prevention: MacGregor's 2006 RCT (N=35 women, 6-cycle crossover) of estradiol gel 1.5 mg/day started 2 days before menses showed reduced migraine incidence during the perimenstrual window but with a rebound increase in attacks in the 5 days after stopping the gel MacGregor et al. 2006. Two later RCTs of transdermal estradiol patches were null. The mechanism is sound (smoothing the estrogen drop) but the dosing window is finicky.
Magnesium for menstrual migraine has one small (N=20) double-blind crossover RCT: oral magnesium pyrrolidone carboxylic acid 360 mg/day from cycle day 15 through next menses reduced headache days and premenstrual complaints vs placebo Facchinetti et al. 1991. Single small study, but cheap, low-risk, mechanistically plausible.
Continuous / extended-cycle combined hormonal contraception (eliminating or extending the pill-free interval that produces the estrogen withdrawal) is the most decisive structural intervention when not contraindicated. Calhoun's case series of women with menstrually related migraine on continuous low-dose ethinyl estradiol reported elimination of menstrual migraine in roughly 80β90% of evaluable patients; aura frequency in women with aura also dropped Calhoun et al. 2012. Restricted to women without migraine with aura, per WHO MEC contraindication WHO 2015.
Acute treatment: triptans are first-line. Sumatriptan and rizatriptan have the highest 2-hour pain-free rates in network analyses (~60% pain-free at 2 hours); recurrence within 24 hours is elevated in perimenstrual attacks vs nonmenstrual, which is the operative wrinkle Hu et al. 2013. For women with high recurrence, a long-half-life triptan (frovatriptan, naratriptan) at attack onset reduces same-day rebound.
protocol
Tiered, depending on attack predictability, severity, and cycle regularity. (1) Track cycle and attack timing for 2β3 cycles to confirm the day -2 to +3 pattern β without confirmation, "menstrual" attacks are often actually scattered. (2) Acute: triptan at first warning sign β sumatriptan 50β100 mg or rizatriptan 10 mg, repeat at 2 hours if needed; add naproxen 500β550 mg for the prostaglandin component. (3) Short-term ("mini") prevention for women with regular cycles and predictable attacks: frovatriptan 2.5 mg twice daily Γ 6 days starting 2 days before expected menses; or naproxen 550 mg twice daily Γ 7 days same window Silberstein et al. 2004 Sances et al. 2008. (4) Hormonal stabilisation for women on or considering combined hormonal contraception (and without aura): switch to continuous / extended-cycle dosing to eliminate the hormone-free interval Calhoun et al. 2012. (5) Background magnesium 300β400 mg/day luteal phase forward is low-cost, low-risk add-on Facchinetti et al. 1991. (6) For women already on a CGRP monoclonal antibody (erenumab, fremanezumab, galcanezumab, eptinezumab), perimenstrual attacks are typically reduced as part of overall migraine reduction but may need supplemental cycle-targeted care.
contraindications
The critical contraindication is structural: combined hormonal contraception is contraindicated in women with migraine with aura, regardless of age, per WHO MEC category 4 (under 35, smoking) and category 3 (under 35, non-smoking); strict contraindication over 35 WHO 2015. The joint effect of combined estrogen-containing contraceptive use plus migraine with aura is approximately a 6-fold increase in ischemic stroke risk vs either factor alone Sheikh et al. 2018. Progestin-only methods (progestin-only pill, levonorgestrel IUD, etonogestrel implant) are not contraindicated and are the appropriate contraceptive choice in this group.
Triptan contraindications: uncontrolled hypertension, ischemic heart disease, prior stroke or TIA, Prinzmetal angina, peripheral vascular disease, hemiplegic and basilar migraine, pregnancy (relative). Frovatriptan and other long-half-life triptans share these.
NSAIDs: peptic ulcer disease, CKD, anticoagulants, third-trimester pregnancy.
misconceptions
Three load-bearing ones. (1) "My monthly headaches are normal β it's just my period." A disabling, light-and-sound-sensitive, vomit-inducing headache occurring at the same point in three of three cycles is a diagnosable condition with cycle-targeted treatments; treating it as period pain misses that the migraine machinery and the cramp machinery are distinct (though prostaglandins drive both) and that short-term triptan prevention exists. (2) "The pill helps menstrual migraine." Combined hormonal contraception with the standard 7-day pill-free interval often worsens menstrual migraine by adding a second, sharper estrogen drop each month β and is contraindicated in the aura subgroup for stroke-risk reasons WHO 2015 Sheikh et al. 2018. Continuous dosing (no pill-free week) is the configuration that helps. (3) "It's the same as my other migraines." Perimenstrual attacks are longer (37β50% longer duration in within-woman analyses), more disabling, more likely to recur within 24 hours, and less responsive to standard acute treatment than the same woman's nonmenstrual attacks PavloviΔ et al. 2015 MacGregor 2021.
audience
Reproductive-age women with confirmed migraine and a documented cycle-attack association in β₯2/3 cycles. Sub-audiences with materially different protocols:
- Migraine with aura: CHC is contraindicated; progestin-only contraception only; same short-term mini-prevention applies WHO 2015.
- Perimenopause (~40β55): the estrogen drop becomes erratic and larger as cycles destabilise; menstrual migraine frequency and severity typically rise before they fall post-menopause. Continuous-dosing HRT (low-dose transdermal estradiol) can stabilise; oral HRT with cyclic dosing can worsen MacGregor 2021.
- Pregnancy: 60β80% of menstrual migraine sufferers improve substantially in the second and third trimesters as estradiol rises 30β40Γ and stops cycling. Postpartum estrogen crash often brings attacks back.
- Irregular cycles / PCOS: short-term mini-prevention is harder to time; continuous-dosing CHC or daily preventive approaches better fit.
alternatives
Alternatives to triptan-based mini-prevention: NSAID mini-prevention (naproxen 550 mg bid Γ 7 days); magnesium luteal-phase loading; non-invasive vagus nerve stimulation (small open-label study; emerging evidence); continuous-dosing CHC (structural elimination). Alternatives to acute triptan: gepants (rimegepant, ubrogepant) β newer small-molecule CGRP-receptor antagonists with fewer cardiovascular contraindications than triptans and useful for the aura subgroup who cannot take CHC. CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) for women with frequent attacks across the cycle, of which menstrual attacks are a subset; daily preventives (propranolol, topiramate, amitriptyline) when mini-prevention is insufficient.
failure-modes
Mistiming the mini-prevention window is the dominant failure mode: starting frovatriptan or naproxen on day 1 of bleeding misses the day -2 to -1 trigger that has already fired. Cycle tracking for 2β3 cycles before starting is what makes the protocol work. Treating recurrence as failure: perimenstrual attacks recur within 24 hours more often than nonmenstrual ones; a single triptan dose isn't a failed regimen, it's the cue for a long-half-life agent or scheduled re-dose. Adding CHC without cycle adjustment in a woman with migraine without aura often worsens attacks by adding a sharper estrogen drop each pill-free week; switching to continuous or extended-cycle dosing is the fix, not stopping CHC. Missing aura: visual scotoma in the 20 minutes before headache changes everything about contraceptive choice and stroke risk, and is frequently underreported because the woman dismisses it.
practicalities
Cycle tracking via app or paper diary for 2β3 cycles is free. Triptans are mostly generic (sumatriptan, rizatriptan, naratriptan, frovatriptan) and inexpensive in most healthcare systems; frovatriptan is sometimes the costliest and not universally stocked. Naproxen is OTC. Magnesium glycinate or pyrrolidone is OTC, ~$5β15/month. Continuous-dosing CHC requires prescriber buy-in; some prescribers default to cyclic dosing. CGRP monoclonal antibodies are expensive ($600β$1,000/month USD without coverage) and require failure on first-line preventives for insurance authorisation in most systems.
stakes
Untreated menstrual migraine in a regularly cycling woman costs roughly 12β36 days/year to attacks (1β3 days per cycle Γ 12 cycles), with the AMPP cohort showing women with menstrually associated migraine had higher MIDAS disability scores and more lost workdays than women with migraine not associated with menses PavloviΔ et al. 2015. The compounding cost is anticipatory: a woman who knows her migraine will hit on day 1 reorganises plans, declines commitments, and underbooks her perimenstrual week for years. The aura-plus-CHC pathway is the rarer, harder stake: stroke at 30 in a never-smoker is the visible failure case of contraceptive prescribing that ignored aura Sheikh et al. 2018.
payoff
Successful short-term prevention typically returns 1β3 days/cycle, 12 cycles/year β on the order of 2β6 working weeks of lost time recovered. PavloviΔ's AMPP analysis quantified the QoL gap between menstrually associated and non-associated migraine; closing it via mini-prevention puts a substantial dent in MIDAS scores. The structural intervention β continuous CHC for non-aura women β eliminates menstrual migraine in 80%+ of evaluable cases Calhoun et al. 2012, which is closer to a category change than a frequency reduction.
history
Hippocrates described menstruation-linked headache; the modern formulation begins with Somerville's 1971β72 papers on perimenstrual estradiol manipulation, which experimentally separated the estrogen drop from the bleed as the trigger. ICHD-1 (1988) did not subclassify menstrual migraine; ICHD-2 (2004) introduced PMM and MRM as appendix criteria, retained in ICHD-3 (2018), still in the appendix rather than the main classification β reflecting the field's unresolved view on whether menstrual migraine is a distinct disorder or a triggered subtype ICHD-3, 2018.
out-of-scope
General migraine prevention strategy (sleep regularity, hydration, trigger reduction beyond cycle) β covered by a generic migraine entry. Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) β overlapping perimenstrual symptoms, distinct entities. CGRP monoclonal antibodies as primary preventives β covered when the broader migraine entry exists. HRT prescribing decisions in late perimenopause β overlaps with the menopause entry. Endometriosis as an interacting condition β separate entry.
The credibility range
Optimist case
Menstrual migraine is a well-characterised, treatable subtype with a clear mechanism (estrogen withdrawal β CGRP release), validated diagnostic criteria, and Class I RCT evidence for both short-term prevention (frovatriptan, naratriptan) and a structural cure for the non-aura majority (continuous CHC). Women who recognise the pattern and follow a cycle-timed protocol reliably get 1β3 days/month back. Identifying aura in this group is one of the highest-leverage primary-care interventions in women's health β preventing avoidable ischemic stroke in young women.
Skeptic case
The estrogen-withdrawal hypothesis, despite wide acceptance, has limited definitive evidence; Raffaelli's 2023 systematic re-review found the supporting literature methodologically thin Raffaelli et al. 2023. Pure menstrual migraine, the cleanest test of the hypothesis, is under 1% prevalent β the field is essentially studying a probabilistic clustering, not a distinct disease Verhagen et al. 2022. RCTs of perimenstrual estradiol replacement have been mixed, with rebound attacks after stopping the gel; if estrogen withdrawal were the whole story, this should be a clean cure. The short-term triptan and NSAID RCTs are positive but small (typical N=20β60); the meta-analysis pooled efficacy is modest in absolute terms (numbers needed to treat ~3β4 for one additional headache-free perimenstrual period) Hu et al. 2013. ICHD-3 still relegates menstrual migraine to the appendix.
Author's call
Treat it as a real, well-evidenced clinical entity for practical purposes β the cycle-timing pattern is reproducible, the mini-prevention RCTs are Class I even if the population sizes are modest, and the contraceptive-choice consequences (aura + CHC + stroke) are not in serious dispute. The estrogen-withdrawal mechanism is the working model and is good enough to drive treatment, even if the molecular detail is incomplete. evidence: 4, controversy: 2 β the field's open questions are about mechanism granularity and whether to elevate menstrual migraine out of the ICHD appendix, not about whether the pattern exists or whether cycle-timed treatment helps.
Stakeholder and incentive map
- Headache neurologists / IHS β push for ICHD recognition and dedicated trials; balanced incentive.
- Triptan manufacturers β historically funded the frovatriptan and naratriptan short-term prevention trials; clean Class I data despite commercial sponsorship.
- CGRP mAb manufacturers β pushing menstrual migraine subgroup analyses to expand indication; emerging but not yet decisive.
- Obstetric / gynaecology specialty β owns the contraceptive prescribing decision; awareness of the aura + CHC contraindication is uneven and the highest-stakes patient-safety question in this space.
- Primary care β often the first to see and miss the pattern; cycle tracking and aura screening are routinely skipped in workup of "bad period headaches."
- Women patients β historically dismissed ("it's just your period"); community channels (forums, advocacy groups like American Migraine Foundation) have driven much of the recent visibility.
Population variability
- Reproductive-age vs perimenopausal: perimenopause amplifies the estrogen drop's amplitude and irregularity; menstrual migraine often worsens before improving post-menopause MacGregor 2021.
- Aura vs without-aura: aura subgroup faces the CHC contraindication; ~30% of migraineurs have aura.
- Cycle regularity: short-term prevention requires predictable timing; PCOS and irregular cycles tilt toward continuous CHC or daily prevention.
- Concurrent contraceptive use: women on CHC have a pharmacologically driven estrogen drop each pill-free week, distinct from natural cycle attacks but mechanistically identical.
- Genetic / familial: higher concordance in twin studies; first-degree relatives of women with menstrual migraine have elevated risk MacGregor 2021.
Knowledge gaps
No definitive estradiol-clamp RCT proving the withdrawal hypothesis at scale; current support is mechanistic and inferential Raffaelli et al. 2023. CGRP monoclonal antibody efficacy in menstrual migraine subgroup is under-studied; current data is post-hoc subset analyses. Optimal continuous-CHC formulation for women with menstrual migraine without aura has not been compared head-to-head. Gepant (rimegepant, atogepant) role in mini-prevention is being actively trialled but not yet established. Long-term cardiovascular outcomes in women with menstrual migraine specifically β beyond the aura-stroke literature β remain under-characterised.
Scoping vs the topic brief. The brief named pain frequency, mood, sleep, productivity, and contraceptive choice. The article covers all five β pain via mechanism/evidence/protocol, mood via the anticipatory-dread arc in stakes/payoff, sleep via the broken-nights sentence in stakes, productivity via the AMPP disability quantification in stakes and "Friday plan / deadline" framing in payoff, and contraceptive choice as the load-bearing contraindications section.
Why action: decide not respond or do. The core reader task is a clinician-collaborative plan with three branches (mini-prevention timing, contraceptive choice gated on aura, structural switch to continuous CHC) β closer to a decision tree than a habit or a one-shot response. The acute-attack arm reads like respond but is one branch inside the larger decide.
Why applicability: 3 not 2. Population prevalence of true menstrual migraine is ~6β7% of reproductive-age women (Vetvik 2014), which alone reads like a 2. The decision audience is wider: any woman weighing combined hormonal contraception with any history of migraine needs to know about aura screening and the stroke-risk contraindication β that pulls the relevance band up to "one whole sex Γ reproductive age band," matching the spec's 3 anchor.
Why longevity: 1 not 0. Migraine itself is not a longevity intervention. But the contraceptive-choice call in this entry materially averts ischemic strokes in the aura + CHC subgroup (Sheikh 2018). Small population effect, real named pathway, hence 1.
Dream tier. Computed overall β 31, below the 40 threshold, so the dream narrative was optional. Written anyway because the relief lever is strong (days/year recovered, monthly dread eliminated) and the dek + tagline are sharper with it. Tier-appropriate crank: dek leads with felt loss + recovery; tagline goes for the predict-and-pre-empt punchline rather than a transformed-life promise.
Acute-treatment doses in the action callout. Sumatriptan 50β100 mg and rizatriptan 10 mg are standard acute doses for any migraine, not menstrual-specific. Included so the action callout is self-contained for a woman whose only encounter with the catalogue is this entry, but they are not the entry's distinctive contribution. The distinctive piece is the mini-prevention window (frovatriptan / naratriptan / naproxen Γ 5β7 days starting day -2).
What was excluded.
- CGRP monoclonal antibodies as primary preventive. Erenumab, fremanezumab, galcanezumab, eptinezumab β emerging evidence for menstrual migraine subgroup but mostly post-hoc subset analyses; cost and access are barriers; belongs in the broader migraine entry, surfaced here only in out-of-scope.
- Gepants (rimegepant, atogepant, ubrogepant) for both acute and mini-prevention β actively trialled (NCT06806293 for atogepant in menstrual migraine specifically) but not yet first-line; deferred to the general migraine entry.
- Non-invasive vagus nerve stimulation as mini-prophylaxis β one open-label study, not enough to elevate.
- Transdermal estradiol gel for mini-prevention (MacGregor 2006) β positive small RCT but follow-up patch trials were null and the rebound-after-stopping issue makes it third-line at best; in the dossier, not the article.
- PMDD overlap. Mentioned in out-of-scope; warrants its own entry.
Future-link candidates. General migraine entry; combined hormonal contraception entry; progestin-only contraception entry; perimenopause / menopause transition; CGRP monoclonal antibodies as a class; PMDD; endometriosis. The aura-screening question is high-leverage enough to consider a standalone "Aura: how to recognise your own" entry β it gates a lot of contraceptive decisions across the women's-health corner of the catalogue.
Rating tension on controversy: 2. Raffaelli 2023 concluded the supporting evidence base for the estrogen-withdrawal hypothesis is thinner than the field's confidence in it. Could argue for 3 on that basis. Held at 2 because the dispute is about mechanistic detail and ICHD classification, not about whether to time prevention to the perimenstrual window β clinical management is uncontested.
Rating tension on evidence: 4. The frovatriptan trial (N=546) is genuinely Class I. The other RCTs are smaller (N=20β60 for naproxen and magnesium). Network meta-analyses pull the body of evidence toward a coherent picture. 5 would require multiple large RCTs replicated across countries; this is closer to one anchor trial plus convergent smaller signals. 4 is the honest call.
Contraindications field left empty at meta level. The entry as a whole is information / decision-support, not an intervention. Specific protocol arms (CHC, triptans, NSAIDs) have well-flagged contraindications in the body. Populating the meta-level contraindications field would mis-signal that the entry itself is unsafe for those groups, which is not the case β they need different protocol arms.
Menstrual Migraine
A timed five-to-seven-day course of the right pill, starting two days before your period, can turn the monthly disabling headache into nothing at all.
Cheap. Generic triptans, an over-the-counter anti-inflammatory, and magnesium cover most of it β typically under a few hundred dollars a year.
A few cycles of tracking, then five to seven days of pills a month timed to your period. Lighter than a daily preventive.
Two large randomised trials nailed the prevention protocol. The stroke-risk piece for women with visual auras is settled enough to be in global guidelines.
A perimenstrual migraine eats two to four days of clarity per month, plus a fog tail. Stopping it returns the energy you've been writing off as "PMS."
Period-week deep work stops being a coin flip. The afternoon you used to lose in a dark room is the afternoon you keep.
The slow monthly dread of "I know it's coming on day 1" lifts. The week before your period stops being something you flinch toward.
Pain-broken nights around your period stop being the default. The week sleeps cleaner because no attack hijacks it.
If you have visual auras with your headaches, the wrong birth-control pill quietly multiplies your stroke risk for years. Knowing this is the longevity move.